Erik Berntorp
1 – 20 of 329
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
(
- Contribution to journal › Article
- 2023
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in development
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group
(
- Contribution to journal › Scientific review
-
Mark
Clinical, economic, and health-related quality of life burden associated with von Willebrand disease in adults and children : Systematic and targeted literature reviews
(
- Contribution to journal › Scientific review
-
Mark
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia : A review of the literature
(
- Contribution to journal › Scientific review
-
Mark
A need to increase von Willebrand disease awareness : vwdtest.com – A global initiative to help address this gap
(
- Contribution to journal › Scientific review
-
Mark
Area under the curve : Comparing the value of factor VIII replacement therapies in haemophilia A
(
- Contribution to journal › Article
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
(
- Contribution to journal › Article
- 2022
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
(
- Contribution to journal › Article
-
Mark
Alternative payment models for durable and potentially curative therapies : The case of gene therapy for haemophilia A
(
- Contribution to journal › Article
-
Mark
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81–8973
(
- Contribution to journal › Article
-
Mark
Sixth Åland Island Conference on von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications
(
- Contribution to journal › Article
- 2021
-
Mark
A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa
(
- Contribution to journal › Article
-
Mark
Treatment outcomes in persons with severe haemophilia B in the Nordic region : The B-NORD study
(
- Contribution to journal › Article
-
Mark
In response to WFH guidelines for the management of haemophilia, 3rd edition : Is there a difference between extended-half-life FVIII products or not?
(
- Contribution to journal › Letter
-
Mark
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)
(
- Contribution to journal › Article
-
Mark
Optimising prophylaxis in haemophilia A : The ups and downs of treatment
(
- Contribution to journal › Scientific review
-
Mark
Translating the success of prophylaxis in haemophilia to von Willebrand disease
(
- Contribution to journal › Scientific review